ライフサイエンスコーパス: Val

1 Val to Ala substitution at position 49 (V49A) had partic

2 Val(48) and Ile(328) are at the outer end of TM1 and TM2

3 Val-136 and adjacent residues may mediate anesthetic bin

4 Val-70 follows a newly recognized conserved motif, PXGG

5 Val-Pro had the highest ORAC activity (19.45+/-2.15mumol

6 Val/Val mice exhibited robust reductions in spatial work

7 1+/-0.1% Arg, 1.07+/-0.05% Asx, 0.96+/-0.05% Val, 0.48+/-0.03% Thr, 0.35+/-0.03% Phe, and 0.28+/-0.03

8 omprising the hydrophobic residues Phe-1012, Val-1025, Tyr-1089, and Leu-1092).

9 hism Leu-108/Thr-189) or b (Prnp(b), Phe-108/Val-189) is associated with short or long incubation tim

10 n of alpha-helix 1 (residues Cys-11, Glu-12, Val-13, Lys-15, and Glu-16) and residue Glu-88.

11 rried on 16 Met (Val/Met and Met/Met) and 16 Val/Val participants selected from a large pool of healt

12 s (N=71; BDNF genotype: Val/Val (N=12, 17%), Val/Met (N=40, 56.3%), and Met/Met (N=19, 26.8%)) receiv

13 C-terminal residues Ser-178-Val-190 act in concert with the flexible EF3/EF4 loop re

14 Removal of Ser-178-Val-190 generated a C-terminal truncation mutant that fo

15 unique set of amino acid residues (Gln(218), Val(277), and Ala(286)) at the putative PpORS active sit

16 hobic and aromatic residues (Phe-22, Trp-25, Val-23, and Met-27) predominantly involved.

17 Making strategic mutations at Lys-26, Val-51, and Arg-79, we targeted residues predicted to be

18 ions suggest that C-terminal residues Gly-29-Val-40 form a tightly packed core with intermolecular di

19 Position 3 (Val) controls affinity, whereas position 7 (Tyr) acts as

20 ting the hydrophobic core residues, Leu-331, Val-338, and Ile-345, of Hec1 with alanine completely el

21 ydrophobic regions probed at Leu-17, Leu-34, Val-36, and Met-35 side chains were found to be very pro

22 at three amino acid positions (Lys/Asn-392, Val/Met-397, Lys/Arg-409) to alter the strength of inter

23 st that a surface of GRK2, including Leu(4), Val(7), Leu(8), Val(11), and Ser(12), directly interacts

24 sp(10), Tyr(13), Ala(16), Met(17), Gly(475), Val(477), and Ile(485) are more important for kinase dom

25 nase within the amino acid sequence Ser(478)-Val(479)-Leu(480)-Gln(481)-Val(482).

26 sequence Ser(478)-Val(479)-Leu(480)-Gln(481)-Val(482).

27 via the leucine 69 (Leu(69)) and valine 68 (Val(68)) residues.

28 ermediate, thereby establishing the alpha-70(Val-->Ile) intermediate as a reliable guide to mechanism

29 freeze-trapped intermediate of the alpha-70(Val-->Ile) MoFe protein as the Janus intermediate that s

30 residues Phe(63), Leu(64), Glu(77), Thr(78), Val(81), and Arg(82) that underlie IFN-beta-IFNAR1-media

31 e of GRK2, including Leu(4), Val(7), Leu(8), Val(11), and Ser(12), directly interacts with receptors,

32 ping identified the cleavage site as Leu(90)/Val(91) in the 95-amino acid ADRA1D NT domain, suggestin

33 site is only one amino acid N-terminal to a Val/Leu substitution associated with schizophrenia.

34 les conserved nonpolar side chains (Ile(A2), Val(A3), Val(B12), Phe(B24), and Phe(B25)) to engage the

35 rved nonpolar side chains (Ile(A2), Val(A3), Val(B12), Phe(B24), and Phe(B25)) to engage the receptor

36 In addition Val-907 was significantly coupled with Asn-1548 in IIIS6

37 Patients with the A4V (Ala-Val) SOD1 mutation (SOD1(A4V)), the largest mutation pop

38 with azide and alkyne at its termini, N3-Ala-Val-NHCH2-C identical withCH, which is designed to self-

39 ning azide and alkyne at its termini (N3-Ala-Val-NHCH2C identical withCH, 1) was synthesized.

40 To our knowledge, the peptides Gly-Pro-Ala-Val, Val-Cys, and Phe-Phe have not been previously ident

41 Cys]-OH), PanSB1 (DOTA-PEG2-dTyr-Gln-Trp-Ala-Val-betaAla-His-Phe-Nle-NH2), and DOTA-MG11 (DOTA-dGlu-A

42 thylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NHEt), showing excellent tumor localizin

43 -1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-OCH3 (ARBA05, 3) analogues are labeled w

44 -1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Leupsi(CHOH- CH2)-(CH2)2-CH3 (RM7, 2), and t

45 -1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-L eu-NH2 (BAY 86-7548).

46 t GRPr antagonist MJ9, Pip-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2) (Pip, 4-amino-1-carboxymethyl-

47 1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bomb

48 1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bomb

49 -1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (RM2, 1; DOTA:1,4,7,10-tetraazac

50 GRPR antagonist JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) was conjugated to NODA-MPAA for

51 is DOTA-betaAla-betaAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], and NODA-MPAA is 2-[4-(carboxy

52 DA-MPAA-betaAla-betaAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], JMV4168 is DOTA-betaAla-betaAl

53 in children homozygous for the minor allele Val/Val, aOR: 1.25 (0.98-1.60).

54 Specifically, Tyr(135) and Val(141) on the DEa loop were shown to be critical resid

55 required conserved loop C ((137)TP(138) and Val(150)) and loop E ((230)HW(231)) amino acids for bind

56 t amino acid stretches Phe(150)-Glu(152) and Val(166)-Glu(170) of FaeGad bind the terminal galactose

57 mprovement to FcgammaRIIIA (both Phe-158 and Val-158 allotypes), increased ADCC activity in vitro, an

58 s-189), and neutrophil elastase (Val-182 and Val-193) sites.

59 Met-186 and Val-288 in IFP1.4 are responsible for the formation of a

60 ides were Ile-Gln-Ala (beta-CN f187-189) and Val-Glu-Pro (beta-CN f116-118) having ACE IC50 values of

61 the peptide was cleaved between Ala(195) and Val(196) (i.e., 1 aa upstream of the expected position).

62 ly-78, Asp-79, His-81, Asn-235, Thr-267, and Val-368 are proposed to position appropriately the catal

63 ncludes residues Arg-32, Ile-33, Met-34, and Val-35.

64 n-cleaved skeletal actin (between Gly-42 and Val-43).

65 failed to cleave a peptide in which Ala and Val were reversed.

66 hese residues with equally conserved Glu and Val counterpart residues in NusG destabilized interactio

67 ched-chain amino acids (BCAAs) Leu, Ile, and Val are among nine essential amino acids that must be ob

68 d-chained amino acids (BCAAs) (Leu, Ile, and Val) and their catabolites, propionylcarnitine and butyr

69 The Leu and Val isomer investigation and trends revealed by our anal

70 tical functions, S. aureus represses Leu and Val synthesis, instead preferring to acquire them from t

71 t BcaP, is required for transporting Leu and Val to be used for iso-BCFA synthesis.

72 adsorption of structural isomers of Leu and Val, which exhibit a correlation between the position of

73 ts of the methyl groups of the Ile, Leu, and Val residues at two static magnetic fields.

74 for the methyl side chains on Ile, Leu, and Val residues showed changes in conformational exchange d

75 conserved loops; Pro-135 in a short loop and Val-70 in a longer loop.

76 of the reported differences in human Met and Val carriers across working memory, fear processes and s

77 these functions between sibling Met/Met and Val/Val mice.

78 ded an unambiguous identification of Nva and Val since the v ion was generated only when Val was pres

79 However, when both Nva and Val were present in one peptide, the observation of inte

80 ntrast, the lactotripeptides Ile-Pro-Pro and Val-Pro-Pro, which were widely used as ingredients for h

81 of healthy adolescents stratified by sex and Val(158)Met genotype (n=1133), we examine BOLD responses

82 residue in this core (Met(25) in ssSPTa and Val(25) in ssSPTb) was identified which confers specific

83 acids (Ala, Asp, Glu, His, Lys, Pro, Thr and Val), incorporating a range of side-chain functionality.

84 with binding guanine in VldE (Asn, Thr, and Val) are similar in S. venezuelae OtsA (Asp, Ser, and Ph

85 ing hydrogen bonds between Asn-2-rho-TIA and Val-197, Trp-3-rho-TIA and Ser-318, and the positively c

86 (JA) to at least Ile, Leu, Met, Phe, Trp and Val and both osjar1 alleles had substantial reduction in

87 t high rates and for Gly, Lys, Phe, Tyr, and Val at moderate or low rates, respectively.

88 s with the Methionine (Met)/Valine (Val) and Val/Val genotypes showed higher fractional anisotropy an

89 ntly different between Met/Met, Met/Val, and Val/Val carriers in each group, which indicated that the

90 The PC inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone significantly suppressed

91 Tight packing of ARRDC3 Val-352', part of a 310 helix at the C terminus of PPXY1

92 the most potent peptides were identified as Val-Glu-Leu-Tyr-Pro, Ala-Phe-Val-Gly-Tyr-Val-Leu-Pro and

93 -acrylamido-phenylalanine (AcrF) mutation at Val-216 that leads to an increase in catalytic efficienc

94 The valve at Val(27) remains on average quite narrow in all protonati

95 ated changes in estradiol secretion and BDNF Val(66)Met genotype on measures of hippocampal function

96 w PET in 39 healthy women genotyped for BDNF Val(66)Met, and a confirmatory data set was obtained wit

97 ied the effect of the common functional BDNF Val(66)Met (rs6265) polymorphism on rewarding experience

98 effects of scopolamine were assessed in BDNF Val/Met knock-in mice, in which BDNF processing and rele

99 ensor imaging to examine the effects of BDNF Val(66)Met genotype on white matter microstructure in a

100 healthy controls were genotyped for the BDNF Val(66)Met polymorphism and underwent the monetary incen

101 an evidence regarding the effect of the BDNF Val(66)Met polymorphism on DA-mediated responses to stre

102 The BDNF Val(66)Met polymorphism, a possible risk variant for men

103 ypothesis that cellular sequelae of the BDNF Val(66)Met SNP interface with aspects of schizophrenic h

104 ration in women that the effects of the BDNF Val/Met polymorphism on hippocampal function are selecti

105 Individuals with the BDNF Val/Val (valine allele) polymorphism showed better memor

106 and brain-derived neurotrophic factor (BDNF(Val/Val), BDNF(Met)) in the extent to which they moderat

107 ity time in the forced swimming test in BDNF(Val/Val) but not in BDNF(Met/Met) mice.

108 Wild-type (BDNF(Val/Val)) and homozygous BDNF Val66Met (BDNF(Met/Met)) m

109 3 years, whereas Abeta(+)varepsilon4(+)/BDNF(Val/Val) individuals can expect a similar degree of impa

110 54 months compared with varepsilon4(-)/BDNF(Val/Val) participants (d=0.90-1.02).

111 ced in BDNF(Met/Met) mice compared with BDNF(Val/Val) mice.

112 ent active site inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone.

113 xial contacts do not engage the mutant beta6 Val and its nonmutant receptor region on an adjacent mol

114 results suggest that an interaction between Val(48) and Ile(328) stabilizes the closed channel and t

115 y was, however, found to be stronger between Val-907 in IIS4-S5 and Ile-1013 in IIS6.

116 otocol and Amyloid beta (39-42) peptide (Boc-Val-Val-IIe-Ala-OMe), following solution-phase strategy

117 loop A ((63)EKP(65) and Asp(69)) and loop C (Val(141), His(151), and Leu(154)).

118 implications for future satellite lidar Cal/Val efforts, because planned satellite lidars measuring

119 Meaningful Cal/Val requires intercomparison data sets with small enough

120 ble along-track averaging for meaningful Cal/Val.

121 Several Calibration/Validation (Cal/Val) studies for CALIOP conducted with ground-based lida

122 tive PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22).

123 n between prenatal maternal smoking and COMT Val(158)Met in conduct problems and crime in the 1993 Pe

124 t mouse lines, which carry either human COMT Val or Met alleles via gene targeting.

125 recall of remote memories as silencing COMT Val overexpression starting from 30 days after the initi

126 overexpressing the human COMT-Val gene (COMT-Val-tg) present exaggerated remote memories (>50 days) w

127 ransgenic mice overexpressing the human COMT-Val gene (COMT-Val-tg) present exaggerated remote memori

128 cue the altered remote memory recall in COMT-Val-tg mice and increased PFC dopamine levels.

129 hereas the weakest-binding analogs contained Val, Ile, and Leu substitutions.

130 up B (CsA, 30 mg/kg per day), group C (CsA + Val, 30 + 30 mg/kg per day), and group D (Val, 30 mg/kg

131 that replacement of Lys-377 with either Cys, Val, Arg, or Asp disables both Na(+) and melibiose bindi

132 H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) fragment 4-11 were synthesized to explore the in

133 + Val, 30 + 30 mg/kg per day), and group D (Val, 30 mg/kg per day).

134 near tripeptide l-delta-aminoadipoyl-l-Cys-d-Val (ACV) on the pathways to a number of important antib

135 nt of C-terminal di-Gly of ubiquitin with di-Val or di-Arg enhances CXCR4 mediated effects on cAMP le

136 , w ions, which can be used to differentiate Val and Nva.

137 in the corresponding HbA Evans (alpha62(E11)Val --> Met).

138 of adult Hb (HbA) Bristol-Alesha (beta67(E11)Val --> Met) that were associated with hemolytic anemia.

139 ts of human fetal Hb Toms River (gamma67(E11)Val --> Met) and beta subunits of adult Hb (HbA) Bristol

140 plasmin (Lys-189), and neutrophil elastase (Val-182 and Val-193) sites.

141 Thus, these two residues, especially Val-89 at the lobby region, are crucial for the entrance

142 n of any of the 20 canonical amino acids for Val-216, indicating that an expanded genetic code may of

143 ation of the adjacent GUA triplet coding for Val at the aminoacyl (A) site.

144 d SERCA-PLB binding, intermolecular FRET for Val(49)-stop (V49X) truncation mutant was paradoxically

145 as base, beta-ketosulfonamides derived from Val, Leu or Ile gave the expected beta-keto-alpha,alpha-

146 o characterize Nva and differentiate it from Val (Valine), a systematic study was conducted using hot

147 etermined mainly by steric restrictions from Val-136 on the beta2-subunit and favorable interactions

148 anchors in a hydrophobic pocket on Galphai1 (Val-34, Leu-194, Phe-196, Phe-336, Thr-340, Ile-343, and

149 Patients (N=71; BDNF genotype: Val/Val (N=12, 17%), Val/Met (N=40, 56.3%), and Met/Met

150 ly possessing lower activity BDNF genotypes (Val/Met, Met/Met).

151 stretches of rare codons, Leu(UUA)-Gly(GGU)-Val(GUA).

152 is-Asn-Pro, Cys-Ile-Gln-Pro-Val, Cys-Arg-Gln-Val-Phe) vs. 14 volatile compounds belonging to relevant

153 tics and a caspase-3 enzyme specific Asp-Glu-Val-Asp (DEVD) peptide.

154 Leu-Ala-Pro, Leu-Leu-Ala-Pro and Met-Ala-Gly-Val-Asp-His-Ile, with IC50 values in the range 43-159 mu

155 % MS SI restoration for the Z-Gly-Gly-Val and bradykinin peptides were 75-83% while % MS SI re

156 sense mutations Lys27Met (K27M) and Gly34Arg/Val (G34R/V) in genes encoding histone H3.3 (H3F3A) and

157 Ile > His >3,4-dihydroxyphenylalanine, Arg > Val > Lys, Tyr, Pro > hydroxyproline > alpha-aminobutyri

158 gnificant effect of BDNF (Met(66) carriers > Val/Val) on brain responses during the anticipation of m

159 lls lines carrying homozygous YARS2 p.191Gly>Val and m.11778G>A mutations.

160 ents both carrying homozygous YARS2 p.191Gly>Val and m.11778G>A mutations.

161 The 191Gly>Val mutation reduced the YARS2 protein level in the muta

162 The YARS2 p.191Gly>Val mutation worsened the respiratory phenotypes associa

163 or both m.11778G>A and heterozygous p.191Gly>Val mutations and symptomatic subjects harboring m.11778

164 harboring m.11778G>A and homozygous p.191Gly>Val mutations) and controls lacking these mutations.

165 ON susceptibility allele (c.572G>T, p.191Gly>Val) in YARS2 gene encoding mitochondrial tyrosyl-tRNA s

166 The hierarchy Leu>Met>Ile>Val at the C-terminal position was determined for all me

167 and acyl carrier protein (65-74) fragment (H-Val-Gln-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly-OH), following t

168 s have Met in position 129 and the other has Val.

169 The branched-chain amino acids (BCAAs) Ile, Val, and Leu are essential nutrients that humans and oth

170 The last 3 residues of NaV1.5 (Ser-Ile-Val) constitute a PDZ domain-binding motif that interact

171 idespread increases in radial diffusivity in Val/Val homozygotes compared with Met-allele carriers, p

172 hydrogenase, AtHDH1 (At4g20930), involved in Val degradation.

173 recollection increased significantly more in Val/Val individuals than in Met carriers in parietal and

174 s points to a role of the enzyme not only in Val but possibly also in Ile metabolism.

175 YXXPhi (where X is any amino acid and Phi is Val, Leu, or Ile) endocytic motif that, when transferred

176 eduction in content of JA-Ile, JA-Leu and JA-Val in florets.

177 at the N terminus: the tertiary amino acid L-Val induces a left-handed type II beta-turn in both the

178 f two different dipeptide nanotubes: l-Ala-l-Val and its retro-analog l-Val-l-Ala.

179 A designed beta-sheet-forming l-Ala-l-Val dipeptide containing azide and alkyne at its termini

180 anotubes: l-Ala-l-Val and its retro-analog l-Val-l-Ala.

181 ormula of the native L3P as D-Phe-N-Methyl-L-Val-L-Ala-OMe attached in N-ter to a 20-carbon fatty aci

182 the results for D + L mixtures of Ala, Leu, Val, and Pro.

183 Phe-Leu, Trp-Val, His-Leu, Glu-Lys, Ala-Leu, Val-Ala, Ser-Leu and Gly-Leu) inhibited DPP-IV.

184 analysis of a polar mixture composed of Leu-Val, Leu-Tyr, Gly-Tyr, and Ala-Tyr dissolved in DMSO-d6/

185 by the thrombin specific cleavage site (Leu-Val-Pro-Arg-Gly-Ser) has been used to fabricate an ultra

186 were observed in other behaviors, with male Val/Val mice exhibited lower prepulse inhibition compare

187 a single-pulse TMS study carried on 16 Met (Val/Met and Met/Met) and 16 Val/Val participants selecte

188 significantly different between Met/Met, Met/Val, and Val/Val carriers in each group, which indicated

189 es would produce the tripeptide Phe-N-Methyl-Val-Ala with a lipid moiety, termed lipotripeptide (L3P)

190 that a substitution in the penultimate MftA Val-29 position causes the accumulation of an MftA** min

191 measurements further suggest that Lys[Z-NO2]-Val interacts with discrete residues in TMH 2 that are i

192 After demonstrating that Lys[Z-NO2]-Val, the strongest inhibitor of hPEPT1, also acts as a h

193 Administration of Val might lead to amelioration of CsA nephrotoxicity by

194 R) also revealed that oral administration of Val-Glu-Leu-Tyr-Pro can decrease systolic blood pressure

195 ucial for the unambiguous differentiation of Val and Nva.

196 es access to the backbone carbonyl groups of Val 494 and Pro 495.

197 of FGF14 where an alanine (Ala) mutation of Val-160 impaired binding to Nav1.6 but had no effect on

198 COX-2 interactions revealed that mutation of Val-434 to Ile significantly reduces inhibition by melox

199 In contrast, mutations of Val(168) or Asn(171) in the upper site, which are unique

200 the mutants if cultivated in the presence of Val or Ile but not in the presence of leucine.

201 aintained when Cys63 is replaced with Ala or Val.

202 ps based on the administration of CsA and/or Val: group A (control, 1 mL/kg per day of olive oil as v

203 dary structure are hydrophobic (e.g., Ile or Val) or only moderately polar (e.g., Thr).

204 idue 129 is polymorphic, being either Met or Val.

205 aa-Ala-Y (where Glp=pyroglutamyl; Xaa=Phe or Val; and Y=pNA [p-nitroanilide], AMC [4-amino-7-methylco

206 st increases in antibodies containing Trp or Val motifs.

207 han-containing dipeptides such as Ile-Trp or Val-Trp, which were recently found in food protein hydro

208 amily members: a hydrophobic residue (Tyr or Val) in the +2 position specifies interaction with SEC24

209 and Trp-483 could form a pocket that orients Val-250 to interact with the dNTP.

210 R. hookeri wine contained more (p<0.05) Phe, Val, Ala, Gly, Pro, Asp, Asn, His and Lys than E. guinee

211 scribe new HsTX1 analogues with an Ala, Phe, Val or Abu substitution at position 14.

212 e identified as Val-Glu-Leu-Tyr-Pro, Ala-Phe-Val-Gly-Tyr-Val-Leu-Pro and Glu-Lys-Ser-Tyr-Glu-Leu-Pro.

213 ICHOS membrane insertion is promoted by poly-Val peptides present in the membrane.

214 con-mediated folding of the WT pro-SP-C poly-Val and a designed poly-Leu transmembrane (TM) segment i

215 The human gene contains a polymorphism (Val(158)Met) that alters enzyme activity and influences

216 Ala-Cys-Cys-Glu-His-dPhe-Arg-Trp-Cys-Arg-Pro-Val-NH 2}, RTD-beta-Ala-(Arg(11))CCMSH (2), RVD-beta-Ala

217 ides Cys-Ile-His-Asn-Pro and Cys-Ile-Gln-Pro-Val while low response was achieved for the dipeptide.

218 thione, Cys-Ile-His-Asn-Pro, Cys-Ile-Gln-Pro-Val, Cys-Arg-Gln-Val-Phe) vs. 14 volatile compounds belo

219 the decapeptide Gramicidin S cyclo(d-Phe-Pro-Val-Orn-Leu-)2 (GS).

220 ntly of AHAS and IPMS AHAS and IPMS regulate Val and Leu homeostasis, where AHAS affects total Val+Le

221 We mutagenized the residue Val-136, which lines the anesthetic-binding cavity, its

222 nts identified three transmembrane residues (Val-86, Lys-93, and Asn-258) that form a putative barrie

223 ar docking studies suggested three residues, Val(567), Glu(568), and Glu(571), located at the interfa

224 0.53-0.79, P=1.81 x 10(-5)) and COMT rs4680 (Val (G) allele: OR=1.27, 95% CI: 1.14-1.42, P=2.49 x 10(

225 mammals, the Cebidae Pro(8)OXT and Saguinus Val(3)Pro(8)OXT taxon-specific variants act as equi-effi

226 e residues contribute to cation selectivity (Val-86 and Asn-258), the transition between the two open

227 ELPs are protein polymers of the sequence (Val-Pro-Gly-Xaa-Gly)n, where the identity of Xaa and n d

228 hr-18 residue in the small subunit with Ser, Val, Gln, Gly, or Asp, and we analyzed the effects of th

229 airs d/l-Ala, -Asp, -Glu, -His, -Leu, -Ser, -Val and the three achiral amino acids Gly, beta-Ala, and

230 Ser-Val and Ile-Phe were shown to exhibit ACE inhibitory act

231 substitutions at the Val-65-equivalent site (Val-64) in Kir6.2 indicated no major effects on channel

232 The site-specific (Val(344)-Thr(345)) and rapid (seconds to minutes) NE-bas

233 the transition between the two open states (Val-86), open channel stability, and the hydrogen-bondin

234 By swapping Val (V63) with Phe, AtPOT1bOB1 gained the capacity to bi

235 xploitative, behavior in Met/Met rather than Val/Val subjects.

236 We demonstrate that Val-boroPro mediates tumor eradication by accelerating t

237 Finally, we show that Val-boroPro has potent adjuvant properties resulting in

238 We therefore suggest that Val(3)Pro(8)OXT and Pro(8)OXT are functional variants, w

239 urthermore, mutagenesis studies suggest that Val-499 is the primary site responsible for these change

240 Lineweaver-Burk plots suggest that Val-Glu-Leu-Tyr-Pro acts as a non-competitive inhibitor

241 ly lower frontal DA based on genotype at the Val(158)Met polymorphism in the COMT gene.

242 of leucine and alanine substitutions at the Val-65-equivalent site (Val-64) in Kir6.2 indicated no m

243 ed analogues have a cis-configuration at the Val-Dil amide bond in their functionally relevant tubuli

244 The present study is aim at evaluating the Val effect in alleviation of CsA nephrotoxicity by proba

245 mparison individuals with genotyping for the Val(66)Met SNP and [(15)O]H(2)O positron emission tomogr

246 the simulations for the Met-129, but not the Val-129, protein.

247 (2h)J(NN), attributed to optimization of the Val N-H...Ndelta1 His H-bond.

248 ngs are convergent with human studies of the Val(158)Met polymorphism, and suggest that COMT's effect

249 plasma and reduced global flexibility of the Val-213 variant most likely improve its local availabili

250 capone treatment significantly reversing the Val/Val alternation deficits.

251 antly lower functional connectivity than the Val/Val genotype.

252 These structures show that the Val-216-AcrF mutation leads to conformational changes in

253 These results suggest that the Val-Glu-Leu-Tyr-Pro would be a beneficial ingredient for

254 MTS did not open P2X2 receptors in which the Val(48) side chain was removed (P2X2(V48G/I328C)).

255 s among the three protein variants, with the Val-36 site displaying the most variability.

256 BDNF Val66Met genotype (30 patients with the Val/Val BDNF allele, 25 patients with the Met-66 allele)

257 n of Asp-96 to Val in mitoNEET or Asp-123 to Val in Miner1 facilitates nitric oxide binding in the [2

258 One mutant, GVSK (Gly(159) to Val, Ser(208) to Lys), contains mutations in regions of

259 nitric oxide, a single mutation of Asp-96 to Val in mitoNEET or Asp-123 to Val in Miner1 facilitates

260 ary core around Lys(11) but makes changes to Val(8) on the exterior side of the beta-strand, possibly

261 visuomotor associative learning, compared to Val homozygotes.

262 One Glu to Val mutation in the active site of the homologous alpha-

263 Here we show that a de novo Glu183 to Val (E183V) mutation in the CaMKIIalpha catalytic domain

264 ele for 3-week vernalization, was mutated to Val(180) in vrn-A1b, encoded by the recessive allele for

265 The Ala212-to-Val (A212V) mutant profoundly limits the product to 5hmC

266 Finally, a Thr-to-Val replacement, which eliminates the Thr Ogamma-H...Nde

267 nd Leu homeostasis, where AHAS affects total Val+Leu and IPMS controls partitioning between these ami

268 ant enzyme revealed that BCAT6 transaminates Val, Leu and Ile as well as the corresponding 2-oxo acid

269 rolled in the Valsartan Heart Failure Trial (Val-HeFT), 3519 had a baseline left ventricular EF of <3

270 valine-m-tyrosine-piperazic acid tripeptide (Val-m-Tyr-Pip) in the sanglifehrin core, stereocenters a

271 A(Gly) and tRNA(Leu), the mitochondrial tRNA(Val) and tRNA(Pro)) were strongly associated with the ob

272 uman mitoribosome when levels of the mt-tRNA(Val) are depleted.

273 ikingly, when steady-state levels of mt-tRNA(Val) are reduced, human mitoribosome biogenesis displays

274 bosomes have been shown to integrate mt-tRNA(Val) compared with the porcine use of mt-tRNA(Phe) We ha

275 Our data demonstrate that only mt-tRNA(Val) or mt-tRNA(Phe) are found in the mitoribosomes of f

276 t of mitochondrial valine transfer RNA (tRNA(Val)) to play an integral structural role, and changes i

277 Trp-Val was predicted to be intestinally neutral (between 25

278 and Trp) and eight dipeptides (Phe-Leu, Trp-Val, His-Leu, Glu-Lys, Ala-Leu, Val-Ala, Ser-Leu and Gly

279 petitive inhibition observed, docking of Trp-Val to the secondary binding sites of XO and DPP-IV is r

280 and Trp-containing dipeptides (Arg-Trp, Trp-Val, Val-Trp, Lys-Trp and Ile-Trp) inhibited XO.

281 nsitized ubiquitin variant that contains two Val to Ala mutations.

282 The BRAF kinase is mutated, typically Val 600-->Glu (V600E), to induce an active oncogenic sta

283 as Val-Glu-Leu-Tyr-Pro, Ala-Phe-Val-Gly-Tyr-Val-Leu-Pro and Glu-Lys-Ser-Tyr-Glu-Leu-Pro.

284 (gamma-melanocyte-stimulating hormone, H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-OH), with it

285 our knowledge, the peptides Gly-Pro-Ala-Val, Val-Cys, and Phe-Phe have not been previously identified

286 Trp-containing dipeptides (Arg-Trp, Trp-Val, Val-Trp, Lys-Trp and Ile-Trp) inhibited XO.

287 CAAs) leucine, isoleucine (Ile), and valine (Val) in the mitochondria efficiently allows the formatio

288 Subjects with the Methionine (Met)/Valine (Val) and Val/Val genotypes showed higher fractional anis

289 It has been demonstrated that Valsartan (Val) as an angiotensin receptor blocker has renoprotecti

290 clear phenotypic differences between various Val-containing haplotypes on COMT-3' untranslated region

291 Val since the v ion was generated only when Val was present, not Nva within the electron energy rang

292 We investigated the mechanism by which Val-boroPro, a boronic dipeptide that inhibits post-prol

293 ports showed that overexpressed ILK in which Val(386) and Thr(387) were substituted with glycine resi

294 y efficacious on Gq and beta-arrestin, while Val(3)Pro(8)OXT showed reduced relative efficacy toward

295 ly, dendritic cell vaccination combined with Val-boroPro treatment results in complete regression of

296 eduction in enzymatic activity compared with Val/Val mice.

297 (1) For steric reasons, epoxyketones with Val or Ile at the P1 position are weak inhibitors of all

298 cortex during failed-inhibition trials with Val homozygotes displaying elevated activation compared

299 e investigated three mutant forms (I14X; X = Val, Ala, Gly) of the enzyme that have increased active

300 pentenyl)alanine at positions 92 and 96; Z = Val, Gly, or Asn at position 95)).